top of page
MENU
MENU
News Release
PURMX Therapeutics Receives Orphan Drug Designation for miR-3140-3p from the U.S. FDA
PURMX Therapeutics Inc. (hereinafter “PURMX”), headquartered in Hiroshima, Japan and led by President and CEO Hidetoshi Tahara, announced...
May 9
PURMX Therapeutics Initiates Phase I Clinical Trial of MIRX002, a Novel MicroRNA-Based Anticancer Drug, for Head and Neck Cancer
PURMX Therapeutics, Inc. (hereinafter referred to as “PURMX”) (Head Office: 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima...
Mar 31
Raised funds through a third-party allocation of new shares from Keio Innovation Initiative, Inc.
PURMX Therapeutics, Inc. (PURMX Therapeutics; Headquarters: Hiroshima, Japan; President: Hidetoshi Tahara; hereafter “the Company”) is...
May 7, 2024
bottom of page